Anavex Life Sciences Corp.
Anavex Life Sciences Corp. is listed today as Anavex Life Sciences Corp.: market value, financials and filings are on its company page.
Funding rounds
0 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2014 | $10 M | Private placement after listing | $10 to $50 million | debt, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Anavex Life Sciences Corp. chose not to state its revenue in its newest notice of a funding round (Apr 2014).
SEC Form D · Apr 2014
The industry group it chose in its notices: Biotechnology.
SEC Form D · Apr 2014
That is all the official record says: Anavex Life Sciences Corp. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Anavex Life Sciences Corp. are on record.
Investors#
No investor of Anavex Life Sciences Corp. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.
Largest shareholders today
Institutions holding Anavex Life Sciences Corp. shares, as of Sep 30, 2026.
- BlackRock, Inc.$16 M8.79%
- Vanguard Capital Management LLC$8 M4.42%
- GMT Capital Corp$5 M2.92%
- Federated Hermes, Inc.$5 M2.79%
- Two Sigma Investments, LP$5 M2.52%
- Geode Capital Management, LLC$5 M2.45%
- State Street Corp$4 M2.11%
- Vanguard Portfolio Management LLC$2 M0.97%
- Summit Financial, LLC$2 M0.96%
- Goldman Sachs Group Inc$2 M0.96%
- Charles Schwab Investment Management Inc$2 M0.96%
- Barclays PLC$2 M0.94%
- Northern Trust Corp$2 M0.85%
- Marshall Wace, LLP$2 M0.82%
- Vanguard Fiduciary Trust Co$1 M0.68%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Christopher U. Missling | Executive officer | Apr 2014 |
| Athanosios U. Skarpelos | Director | Apr 2014 |
| Christopher U. Missling | Director | Apr 2014 |
Went public since 2012. Its SEC number is that of a company listed on a stock exchange.